Neximmune Inc
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a vivo directly injectable modality platform. The company's product candidates incl… Read more
Neximmune Inc (NEXI) - Total Liabilities
Latest total liabilities as of June 2024: $4.94 Million USD
Based on the latest financial reports, Neximmune Inc (NEXI) has total liabilities worth $4.94 Million USD as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Neximmune Inc - Total Liabilities Trend (2018–2023)
This chart illustrates how Neximmune Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Neximmune Inc Competitors by Total Liabilities
The table below lists competitors of Neximmune Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CLANCY EXP
BE:CK1
|
Germany | €2.14 Million |
|
Powerstorm Holdings Inc
PINK:PSTO
|
USA | $103.07K |
|
Filinvest Land Inc
PSE:FLI
|
Philippines | ₱111.22 Billion |
|
Amatheon Agri Holding NV
PA:MLAAH
|
France | €113.23 Million |
|
Global-Estate Resorts Inc
PSE:GERI
|
Philippines | ₱27.63 Billion |
Liability Composition Analysis (2018–2023)
This chart breaks down Neximmune Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 5.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.84 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Neximmune Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Neximmune Inc (2018–2023)
The table below shows the annual total liabilities of Neximmune Inc from 2018 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $5.08 Million | -52.75% |
| 2022-12-31 | $10.76 Million | +47.97% |
| 2021-12-31 | $7.27 Million | -73.12% |
| 2020-12-31 | $27.06 Million | +770.81% |
| 2019-12-31 | $3.11 Million | -6.75% |
| 2018-12-31 | $3.33 Million | -- |